These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12207216)

  • 1. Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study.
    Castiñeiras AA; Pérez-Pascual P; Zarranz JE; Della-Latta P; Herreras A
    Int Microbiol; 2002 Sep; 5(3):139-44. PubMed ID: 12207216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal tuberculosis treated with rifampicin, isoniazid and ofloxacin].
    Alberte A; Martínez-Sagarra JM; Estébanez MJ; Pascual PP
    Enferm Infecc Microbiol Clin; 1992 Apr; 10(4):216-9. PubMed ID: 1606225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
    Tuber Lung Dis; 1992 Feb; 73(1):59-67. PubMed ID: 1326349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
    Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN
    Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary Mycobacterium szulgai infection in an immunocompetent patient.
    Lin JN; Lai CH; Chen YH; Huang CK; Lin HF; Eng HL; Lin HH
    South Med J; 2009 Sep; 102(9):979-81. PubMed ID: 19668034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
    Herbert D; Paramasivan CN; Venkatesan P; Kubendiran G; Prabhakar R; Mitchison DA
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2296-9. PubMed ID: 8891133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial].
    Geijo MP; Herranz CR; Vaño D; García AJ; García M; Dimas JF
    Enferm Infecc Microbiol Clin; 2007 May; 25(5):300-4. PubMed ID: 17504682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Second-Generation Line Probe Assay (Hain MTBDR
    Rockwood N; Wojno J; Ghebrekristos Y; Nicol MP; Meintjes G; Wilkinson RJ
    J Clin Microbiol; 2017 May; 55(5):1508-1515. PubMed ID: 28249999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
    Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multidrug-resistant tuberculosis in Indonesia.
    Hadiarto M; Tjandra YA; Hudoyo A
    Chemotherapy; 1996; 42 Suppl 3():24-9. PubMed ID: 8980865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of multidrug-resistant tuberculosis in Turkey.
    Tahaoğlu K; Törün T; Sevim T; Ataç G; Kir A; Karasulu L; Ozmen I; Kapakli N
    N Engl J Med; 2001 Jul; 345(3):170-4. PubMed ID: 11463011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multidrug-resistant tuberculosis in Taiwan.
    Suo J; Yu MC; Lee CN; Chiang CY; Lin TP
    Chemotherapy; 1996; 42 Suppl 3():20-3; discussion 30-3. PubMed ID: 8980864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
    Ziakas PD; Mylonakis E
    Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013].
    Llerena C; Zabaleta A; Valbuena A; Murcia M
    Biomedica; 2017 Jan; 37(1):96-103. PubMed ID: 28527253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Rustomjee R; Lienhardt C; Kanyok T; Davies GR; Levin J; Mthiyane T; Reddy C; Sturm AW; Sirgel FA; Allen J; Coleman DJ; Fourie B; Mitchison DA;
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):128-38. PubMed ID: 18230244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.